Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.

CONCLUSIONS: Currently,ÃÂ available evidence does not support the overall superiority of any anticoagulant to another. Compared to UFH, citrate probably reduces major bleeding and prevents clotting and probably has little or no effect on death at 28 days. For other pharmacological anticoagulation methods, there is no available data showing overall superiority to citrate or no pharmacological anticoagulation. Further studies are needed to identify patient populations in which CRRT should commence with no pharmacological anticoagulation or with citrate. PMID: 33314078 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33314078?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - December 14, 2020 Category: General Medicine Authors: Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, Kataoka Y Tags: Cochrane Database Syst Rev Source Type: research